TRANSCEND NHL 001: Phase I Study of Lisocabtagene Maraleucel in R/R LBCL

December 7-10, 2019; Orlando, Florida
In the pivotal phase I TRANSCEND NHL 001 study, the CD19-directed CAR T-cell therapy lisocabtagene maraleucel demonstrated robust activity and manageable safety in relapsed/refractory LBCL.
Format: Microsoft PowerPoint (.ppt)
File Size: 244 KB
Released: December 12, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

In this commentary from Clinical Care Options (CCO), Asim V. Farooq, MD and Joann Kang, MD, provide guidance on monitoring and mitigating ocular toxicities associated with antibody-drug conjugates

Asim V. Farooq, MD Joann Kang, MD Released: January 20, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the diagnosis and staging of light-chain amyloidosis

Shaji K. Kumar, MD Released: January 18, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the initial management of light-chain amyloidosis

Vaishali Sanchorawala, MD Released: January 18, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the management of light-chain amyloidosis at relapse

Ankit Kansagra, MD Released: January 18, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings